Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study)

ConclusionThese findings support that diabetic nephropathy combined with hyperuricemia may be associated with kidney dysfunctions. Topiroxostat provides strict control of the serum uric acid level preventing decline of eGFR in these patients.

http://link.springer.com/10.1007/s10157-018-1530-1

Source: Clinical and Experimental Nephrology - January 25, 2018 Category: Urology & Nephrology Source Type: research